Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.

Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.

Main purpose:

Retrospective case study to explore the effect of traditional Chinese medicine on the prevention of SARS-CoV-2.

Secondary purpose:

If there are related side effects after taking Chinese medicine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Pandemic COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Taipei City Hospital

Taipei, 886, Taiwan

About this study

The large-scale coronavirus epidemic is a major global public health challenge in the 21st century. Since the 2003 Severe acute respiratory syndrome (SARS) epidemic spread globally and caused hundreds of deaths, the Middle East respiratory syndrome (Middle East respiratory syndrome, MERS) and coronavirus disease 2019(COVID-19) has caused a large-scale global spread and also caused a huge impact on the public health and medical system. In the country's current epidemic (Aug 1, 2021), more than 15,000 people have been diagnosed, and the number of deaths has exceeded 800. Among them, the Taipei epidemic is the most severe, and the Wanhua District of Taipei City is the hot zone. The investigators will discuss the changes in accumulation incidence rate(CIR) of the community and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak.

This is a retrospective case study to explore the effect of traditional Chinese medicine on the prevention of SARS-CoV-2 and discuss if there are related side effects after taking Chinese medicine.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

From January 1, 2020 to July 31, 2021, Chinese medicine is used for patients with new coronary pneumonia epidemic prevention.

Exclusion criteria

Patients who do not use traditional Chinese medicine for the prevention of new coronary pneumonia.
Patients who have signed and refused to provide medical records.

Treatment and study plan

Jing-Guan-Fang(JGF) : Chinese herbal decoction

Drug

Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.

Other names: Chinese herbal decoction

Primary outcomes

Investigation on the effect of using traditional Chinese medicine to prevent SARS-CoV-2 infection in two groups with cumulative incidence rate(CIR).

Time frame: 18 months

Compare the dangerous states within two groups with CIR.

Sponsors and collaborators

Lead sponsor

Taipei City Hospital

Other Gov

Registry information

Official study title

Taipei City Hospital Linsen Chinese Medicine and Kunming Branch

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: Feb 11, 2022
Registry last updated: Mar 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed